Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models

被引:5
|
作者
Morales, Paula [1 ]
Reggio, Patricia H. [1 ]
机构
[1] Univ N Carolina, Greensboro, NC 27412 USA
关键词
Cannabinoids; Clinical studies; Endocannabinoid system; Experimental models; Synthetic cannabinoids; ACID AMIDE HYDROLASE; CB2; RECEPTORS; IN-VITRO; ENDOCANNABINOID SYSTEM; ALZHEIMERS-DISEASE; MOLECULAR-MECHANISMS; PARKINSONS-DISEASE; THERAPEUTIC TARGET; ANTITUMOR-ACTIVITY; CANCER-TREATMENT;
D O I
10.1007/978-3-030-57369-0_4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In recent years, an increasing number of investigations has demonstrated the therapeutic potential of molecules targeting the endocannabinoid system. Cannabinoids of endogenous, phytogenic, and synthetic nature have been assessed in a wide variety of disease models ranging from neurological to metabolic disorders. Even though very few compounds of this type have already reached the market, numerous preclinical and clinical studies suggest that cannabinoids are suitable drugs for the clinical management of diverse pathologies. In this chapter, we will provide an overview of the endocannabinoid system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.
引用
收藏
页码:47 / 65
页数:19
相关论文
共 50 条
  • [21] Synthetic cannabinoids in the kidneys
    Alp, Alper
    Akdam, Hakan
    Avcioglu, Banu Yilmaz
    Ersan, Sibel
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (01): : 10 - 12
  • [22] Synthetic cannabinoids - Preface
    Pop, E
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (13) : U2 - U2
  • [23] Psychosis and synthetic cannabinoids
    Deng, Huiqiong
    Verrico, Christopher D.
    Kosten, Thomas R.
    Nielsen, David A.
    PSYCHIATRY RESEARCH, 2018, 268 : 400 - 412
  • [24] The Synthetic Cannabinoids Phenomenon
    Karila, Laurent
    Benyamina, Amine
    Blecha, Lisa
    Cottencin, Olivier
    Billieux, Joel
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (42) : 6420 - 6425
  • [25] Regulation of synthetic cannabinoids
    Sumnall, Harry
    LANCET, 2009, 374 (9701): : 1595 - 1595
  • [26] A new emerging problem in pediatric emergency units: Synthetic cannabinoids
    Aladag-Ciftdemir, Nukhet
    Yucel, Ilay
    Duran, Ridvan
    Vatansever-Ozbek, Ulfet
    Acunas, Betul
    TURKISH JOURNAL OF PEDIATRICS, 2016, 58 (05) : 492 - 497
  • [27] Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications
    Suriaga, Armiel
    Tappen, Ruth M.
    Aston, Elizabeth R.
    Chiang-Hanisko, Lenny
    Newman, David
    JOURNAL OF NURSING SCHOLARSHIP, 2023, 55 (03) : 623 - 636
  • [28] Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
    Martinotti, Giovanni
    Santacroce, Rita
    Papanti, Duccio
    Elgharably, Yasmine
    Prilutskaya, Mariya
    Corazza, Ornella
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (05) : 567 - 575
  • [29] Synthetic cannabinoids 2015: An update for pediatricians in clinical practice
    Daniel Castellanos
    Leonard M Gralnik
    World Journal of Clinical Pediatrics, 2016, (01) : 16 - 24
  • [30] Synthetic cannabinoids: Epidemiology, patterns of use and clinical outcomes
    Pelissier-Alicot, Anne-Laure
    TOXICOLOGIE ANALYTIQUE ET CLINIQUE, 2015, 27 (01) : 33 - 40